Multiple Myeloma Clinical Trials in New York, New York

46 studies are recruiting for multiple myeloma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

1. Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

   This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mount Sinai, The Tisch Cancer Instutute, New York, New York

   Locations

   24 in total

   Run by

   Heidelberg Pharma AG

   See if you can join NCT04879043 on ClinicalTrials.gov

2. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

   The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of e…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York, New York

   Locations

   237 in total

   Run by

   Pfizer

   See if you can join NCT05020236 on ClinicalTrials.gov

3. Delayed Toxicities Post-CAR-T

   This is an observational umbrella protocol evaluating toxicities after CAR-T therapy with ciltacabtagene autoleucel (cilta-cel) for RRMM, with a goal to identify key inflammatory features contributing to toxicities, define non-invasive biomarkers to guide clinical monitoring, and evaluate treatment…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mount Sinai, New York, New York

   Locations

   3 in total

   Run by

   Icahn School of Medicine at Mount Sinai

   See if you can join NCT07665307 on ClinicalTrials.gov

4. A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

   The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Laura and Isaac Perlmutter Cancer Center, New York, New York

   Locations

   19 in total

   Run by

   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

   See if you can join NCT06121843 on ClinicalTrials.gov

5. Selinexor and Backbone Treatments of Multiple Myeloma Patients

   This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to b…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Columbia University, New York, New York

   Locations

   25 in total

   Run by

   Karyopharm Therapeutics Inc

   See if you can join NCT02343042 on ClinicalTrials.gov

6. A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

   Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mt Sinai /ID# 251166, New York, New York

   Locations

   46 in total

   Run by

   AbbVie

   See if you can join NCT05650632 on ClinicalTrials.gov

7. A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

   This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that r…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York

   Locations

   42 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT05137054 on ClinicalTrials.gov

8. A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

   The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. In addition, the researchers will find out whethe…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   11 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06083922 on ClinicalTrials.gov

9. A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

   The purpose of this study is to find out whether the combination of elranatamab and cyclophosphamide is an effective treatment for people with relapsed/refractory multiple myeloma (MM) who have risk factors that may affect how well their disease would respond to elranatamab alone.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07454382 on ClinicalTrials.gov

10. The Ambient Light Multiple Myeloma Study

    The aim of this multi-site randomized control trial will be is to assess the impact Systematic lighting on circadian rhythm entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multiple Myeloma Patients undergoing Autologous Stem Cell Transplantation. To achieve this aim, 200 multi…

    Stage

    Not phased

    Ages

    21 and older

    Site

    Icahn Schoool of Medicine at Mount Sinai, New York, New York

    Locations

    2 in total

    Run by

    Icahn School of Medicine at Mount Sinai

    See if you can join NCT05737732 on ClinicalTrials.gov

11. A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

    This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Perlmutter Cancer Center, New York, New York

    Locations

    32 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT05828511 on ClinicalTrials.gov

12. Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease activity of etentamig in combination with a cereblon E3 ligase modulatory drug (CELMoD) agent in adul…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 270282, New York, New York

    Locations

    27 in total

    Run by

    AbbVie

    See if you can join NCT06896916 on ClinicalTrials.gov

13. A Dietary Study for People With Multiple Myeloma

    The purpose of the study is to find out whether a dietary intervention can affect treatment response and/or quality of life for people with newly diagnosed multiple myeloma receiving standard induction chemotherapy with daratumumab (or isatuximab), lenalidomide, bortezomib, and dexamethasone (DRVd)…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07226609 on ClinicalTrials.gov

14. A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

    The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    GSK Investigational Site, New York, New York

    Locations

    181 in total

    Run by

    GlaxoSmithKline

    See if you can join NCT06679101 on ClinicalTrials.gov

15. Study of CAR-T Therapy in Older Patients

    This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life. This is a quality of life study and participating in the study does not involve receiving any treatment, other than the standard treatment for participants' dis…

    Stage

    Not phased

    Ages

    60 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04300998 on ClinicalTrials.gov

16. A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

    A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Mount Sinai Hospital, New York, New York

    Locations

    104 in total

    Run by

    Sumitomo Pharma America, Inc.

    See if you can join NCT04988555 on ClinicalTrials.gov

17. A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

    The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CAR T-cell therapy ide-cel for their disease.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06066346 on ClinicalTrials.gov

18. In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

    The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans ce…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05093335 on ClinicalTrials.gov

19. Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

    The purpose of this study is to better understand the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases. The doctors have identified the patient because 1) they have had a lymphoproliferative disorder suc…

    Stage

    Not phased

    Ages

    Any age

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    6 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT00582621 on ClinicalTrials.gov

20. A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    17 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT05372354 on ClinicalTrials.gov

21. IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

    This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and pr…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NYP/Weill Cornell Medical Center, New York, New York

    Locations

    12 in total

    Run by

    Indapta Therapeutics, INC.

    See if you can join NCT06119685 on ClinicalTrials.gov